Transcriptional regulation of Acsl1 by CHREBP and NF-kappa B in macrophages during hyperglycemia and inflammation
Open Access
- 2 September 2022
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (9) , e0272986
Abstract
Acyl-CoA synthetase 1 (ACSL1) is an enzyme that converts fatty acids to acyl-CoA-derivatives for lipid catabolism and lipid synthesis in general and can provide substrates for the production of mediators of inflammation in monocytes and macrophages. Acsl1 expression is increased by hyperglycemia and inflammatory stimuli in monocytes and macrophages, and promotes the pro-atherosclerotic effects of diabetes in mice. Yet, surprisingly little is known about the mechanisms underlying Acsl1 transcriptional regulation. Here we demonstrate that the glucose-sensing transcription factor, Carbohydrate Response Element Binding Protein (CHREBP), is a regulator of the expression of Acsl1 mRNA by high glucose in mouse bone marrow-derived macrophages (BMDMs). In addition, we show that inflammatory stimulation of BMDMs with lipopolysaccharide (LPS) increases Acsl1 mRNA via the transcription factor, NF-kappa B. LPS treatment also increases ACSL1 protein abundance and localization to membranes where it can exert its activity. Using an Acsl1 reporter gene containing the promoter and an upstream regulatory region, which has multiple conserved CHREBP and NF-kappa B (p65/RELA) binding sites, we found increased Acsl1 promoter activity upon CHREBP and p65/RELA expression. We also show that CHREBP and p65/RELA occupy the Acsl1 promoter in BMDMs. In primary human monocytes cultured in high glucose versus normal glucose, ACSL1 mRNA expression was elevated by high glucose and further enhanced by LPS treatment. Our findings demonstrate that CHREBP and NF-kappa B control Acsl1 expression under hyperglycemic and inflammatory conditions.Keywords
All Related Versions
Funding Information
- National Institutes of Health (P01HL131481)
- National Heart, Lung, and Blood Institute (P01HL131481)
- National Institutes of Health (R01DK099087)
- National Institutes of Health (R21NS110520)
- National Institutes of Health (R01AI148129)
- National Institutes of Health (R01AA011576)
This publication has 32 references indexed in Scilit:
- Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1Proceedings of the National Academy of Sciences, 2012
- ChREBP expression in the liver, adipose tissue and differentiated preadipocytes in human obesityBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2011
- Immediate mediators of the inflammatory response are poised for gene activation through RNA polymerase II stallingProceedings of the National Academy of Sciences, 2009
- Kinetic Complexity of the Global Response to Glucocorticoid Receptor ActionEndocrinology, 2009
- Mammalian Long-Chain Acyl-CoA SynthetasesExperimental Biology and Medicine, 2008
- Conservation analysis predicts in vivo occupancy of glucocorticoid receptor-binding sequences at glucocorticoid-induced genesProceedings of the National Academy of Sciences, 2008
- ChREBP binding to fatty acid synthase and L-type pyruvate kinase genes is stimulated by glucose in pancreatic β-cellsJournal of Lipid Research, 2006
- Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesisCell Metabolism, 2006
- A c-Rel subdomain responsible for enhanced DNA-binding affinity and selective gene activationGenes & Development, 2005
- Murine TOLL-like Receptor 4 Confers Lipopolysaccharide Responsiveness as Determined by Activation of NFκB and Expression of the Inducible CyclooxygenaseJournal of Biological Chemistry, 2000